Medicago and GSK win approval from Health Canada for adjuvanted plant-based COVID-19 vaccine

GlaxoSmith Kline (NYSE:GSK) and Sanofi (NYSE:SNY) recently announced their intent to seek regulatory authorization for an adjuvanted recombinant protein-based COVID-19 vaccine.

Now, GSK and its partner Medicago have received approval from Health Canada for another COVID-19 vaccine, which combines the former’s adjuvant technology with the latter’s plant-derived vaccine. 

Known as Covifenz, the vaccine makes use of plant-based virus-like particles. 

The Health Canada approval covers adults between the ages of 18 to 64.

The agency approved the Novavax COVID-19 vaccine last week.

GSK is also working with K Bioscience in South Korea on an adjuvanted COVID-19 vaccine and with CureVac on a next-generation mRNA vaccine. 

“This first approval is an important milestone in our approach of pairing GSK’s well-established pandemic adjuvant with promising antigens to develop protein-based, refrigerator-stable COVID-19 vaccines to help protect peopl…

Read more
  • 0